Mercer Global Advisors’s Belite Bio BLTE Stock Holding History

Mercer Global Advisors’s Portfolio BLTE Stock Details BLTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.3K	Buy	+80	New	+$12.3K	﹤0.01%	5048

Other funds holding BLTE

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $646M AUM 291.07% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mercer Global Advisors's BLTE Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Belite Bio (BLTE) in Q2 2026: 80 shares worth $12.3K. The stake represents ﹤0.01% of the portfolio and ranks #5048 among its holdings.

42 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

Mercer Global Advisors held 80 shares of Belite Bio worth $12.3K as of Q2 2026.
Belite Bio was a new Mercer Global Advisors position in Q2 2026.
Belite Bio made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5048 holding.
42 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.